Thepatients had been given at least three rounds of chemotherapy previouslyand were then treated with 1 as a single agent.27 It was seen in this trial and subsequent onesthat platinum-sensitive cancers showed a better overall response rateto PARPi compared to platinum-resistant cancers.28,29 Despite this, 1 has shown some success in platinum-resistantcancers in patients with BRCA1/2 mutations.28,30 This diversifies it from the other approved PARPi’s. This evidence concerns the gene BRCA1 and cancer.